Incretin Effect on the Immunological Phenotype

Medical University of Graz15 enrolled

Overview

Assessment of the effect of incretin based therapies (Liraglutide and Saxagliptin) on immune cells in healthy subjects and patients with type 1 diabetes

Assessment of immunological effects of Saxagliptin and Liraglutide on immune cells of the peripheral blood.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Type 1 Diabetes

Interventions

LiraglutideDRUG

once daily subcutaneous injection

SaxagliptinDRUG

once daily tablet

Eligibility

Sex: ALLMin age: 18 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: -healthy subjects or patients with type 1 diabetes Exclusion Criteria: * pregnancy * treatment with GLP-1-Analoga (Liraglutide, Exenatide) * treatment with DPP4-inhibitor (Sitagliptin, Vildagliptin, Saxagliptin) * chronic disease including a long-term medication over 4 weeks per year (except type 1 diabetes)

Locations (1)

Medical University Graz

Graz, Austria

Outcomes

Primary Outcomes

Increase of regulatory FOXP3+ T cells

the effects of incretin based therapy on regulatory FOXP3+ T cells will be measured at baseline and after 4 weeks

Time frame: 4 weeks

Secondary Outcomes

Immunophenotyping

The effect of incretin based therapy on circulating immune cells and cytokine secretion at baseline and after 4 weeks

Time frame: 4 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.